

NOVAVAX INC  
Form 8-K  
June 15, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) June 11, 2012**

**NOVAVAX, INC.**

**(Exact name of Registrant as specified in its charter)**

Delaware  
(State or other jurisdiction of incorporation or  
organization)

0-26770  
(Commission File  
Number)

22-2816046  
(I.R.S. Employer Identification  
No.)

**9920 Belward Campus Drive**

**20850**

**Rockville, Maryland**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (240)  
268-2000

**(Former name or former address, if changed since last report.)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant**

**under any of the following provisions (see General Instruction A.2. below):**

**.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**.. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**.. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**.. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Novavax, Inc. (the “Company”), held its Annual Meeting of Stockholders on June 11, 2012 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders elected Richard H. Douglas, Ph.D., Gary C. Evans and John O. Marsh Jr. J.D., as Class II directors to serve on the Company’s Board of Directors until the Company’s 2015 Annual Meeting of Stockholders. The results of the stockholders’ votes with respect to the election of these directors were as follows:

	For	Withheld	Broker Non-Votes
Richard H. Douglas, Ph.D.	52,789,910	2,340,139	42,044,452
Gary C. Evans	46,633,207	8,496,842	42,044,452
John O. Marsh Jr., J.D.	52,496,537	2,633,512	42,044,452

In addition, the Company’s stockholders voted to ratify the selection of Grant Thornton LLP as the Company’s independent auditor for the fiscal year ending December 31, 2012. The results of the stockholders’ votes with respect to this proposal were as follows:

	For	Against	Abstain
Ratification of Independent Auditor	96,076,677	675,151	422,673

Finally, the Company’s stockholders also voted to increase by 4,000,000 shares the amount of shares that it may offer under the Company’s 2005 Stock Incentive Plan. The results of the stockholders’ votes with respect to this proposal were as follows:

	For	Against	Abstain	Broker Non-Votes
Vote to increase the number of shares under the 2005 Stock Incentive Plan by 4,000,000	44,899,640	9,796,820	433,589	42,044,452

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Novavax, Inc.  
(Registrant)

June  
15,  
2012

By: /s/ John A. Herrmann III

Name: John A. Herrmann III

Title: Vice President, General Counsel and Corporate Secretary